Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
Tag: ICANS
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T
Cytokine Release Syndrome 2.0: Managing Immune-Effector Toxicity as Cell Therapy Moves Earlier, Broader, and Beyond CAR T Review Abstract Purpose: This article reviews cytokine release syndrome (CRS) and related immune-effector toxicities in the expanding era of cellular therapy, with emphasis on practical recognition, risk stratification,
